IL2 and systemic lupus erythematosus: In a recent phase 1b clinical trial of a polyethylene glycol (PEG) conjugate of IL-2 (NKTR-358) in patients with mild to moderate SLE, dose-dependent increases in Tregs (up to 11 fold) were observed, which returned to baseline 20-30 days post-dose (137).